BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BioCentury | Mar 9, 2018
Clinical News

Dermira discontinues development of acne candidate

Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor...
BioCentury | Jan 6, 2017
Clinical News

Olumacostat glasaretil: Ph III CLAREOS-1 and CLAREOS-2 started

Dermira began the identical, double-blind, vehicle-controlled, international Phase III CLAREOS-1 and CLAREOS-2 trials to evaluate twice-daily 5% topical olumacostat glasaretil for 12 weeks in about 1,400 total patients. Patients will be eligible to enroll in...
BioCentury | Dec 3, 2016
Company News

Management tracks

...She was SVP and chief regulatory officer at Aegerion Pharmaceuticals Inc. , which merged with QLT Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...The company hopes to reduce 2017 operating expenses by $25-$35M. Aegerion is merging with QLT Inc. (TSX:QLT...
BioCentury | Aug 8, 2016
Company News

Aegerion endocrine/metabolic news

...molecule microsomal triglyceride transfer protein ( MTTP ; MTP) inhibitor. Aegerion is merging with QLT Inc. (TSX:QLT...
BioCentury | Jun 20, 2016
Financial News

QLT proposes private placement

...QLT Inc. (TSX:QLT; NASDAQ:QLTI), Vancouver, B.C. Business: Drug delivery, Ophthalmic Date announced: 2016-06-15 Type: Private placement...
BioCentury | Jun 20, 2016
Company News

Aegerion, QLT deal

...and own about 33% of the combined newco. QLT shareholders will own the remaining 67%. QLT...
...deal, a syndicate of new investors and existing shareholders will purchase about $22 million in QLT...
...and own about 33% of the combined newco. QLT shareholders will own the remaining 67%. QLT...
BioCentury | Jun 16, 2016
Company News

Aegerion, QLT merging

...Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) and QLT Inc. (TSX:QLT; NASDAQ:QLTI) are to merge in a stock deal to...
...rare disease products and one late-stage rare disease program. Aegerion shareholders are to receive 1.0256 QLT...
...existing QLT and Aegerion investors including Sarissa Capital, is to purchase about $22 million in QLT...
BioCentury | May 16, 2016
Clinical News

DRM01: Phase IIb data

Top-line data from a double-blind, U.S. and Canada Phase IIb trial in 420 patients with moderate to severe facial acne vulgaris showed that twice-daily 7.5% topical DRM01 met the co-primary endpoints of reducing mean inflammatory...
Items per page:
1 - 10 of 818
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BioCentury | Mar 9, 2018
Clinical News

Dermira discontinues development of acne candidate

Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor...
BioCentury | Jan 6, 2017
Clinical News

Olumacostat glasaretil: Ph III CLAREOS-1 and CLAREOS-2 started

Dermira began the identical, double-blind, vehicle-controlled, international Phase III CLAREOS-1 and CLAREOS-2 trials to evaluate twice-daily 5% topical olumacostat glasaretil for 12 weeks in about 1,400 total patients. Patients will be eligible to enroll in...
BioCentury | Dec 3, 2016
Company News

Management tracks

...She was SVP and chief regulatory officer at Aegerion Pharmaceuticals Inc. , which merged with QLT Inc....
BioCentury | Oct 3, 2016
Finance

Dressed in black

...The company hopes to reduce 2017 operating expenses by $25-$35M. Aegerion is merging with QLT Inc. (TSX:QLT...
BioCentury | Aug 8, 2016
Company News

Aegerion endocrine/metabolic news

...molecule microsomal triglyceride transfer protein ( MTTP ; MTP) inhibitor. Aegerion is merging with QLT Inc. (TSX:QLT...
BioCentury | Jun 20, 2016
Financial News

QLT proposes private placement

...QLT Inc. (TSX:QLT; NASDAQ:QLTI), Vancouver, B.C. Business: Drug delivery, Ophthalmic Date announced: 2016-06-15 Type: Private placement...
BioCentury | Jun 20, 2016
Company News

Aegerion, QLT deal

...and own about 33% of the combined newco. QLT shareholders will own the remaining 67%. QLT...
...deal, a syndicate of new investors and existing shareholders will purchase about $22 million in QLT...
...and own about 33% of the combined newco. QLT shareholders will own the remaining 67%. QLT...
BioCentury | Jun 16, 2016
Company News

Aegerion, QLT merging

...Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) and QLT Inc. (TSX:QLT; NASDAQ:QLTI) are to merge in a stock deal to...
...rare disease products and one late-stage rare disease program. Aegerion shareholders are to receive 1.0256 QLT...
...existing QLT and Aegerion investors including Sarissa Capital, is to purchase about $22 million in QLT...
BioCentury | May 16, 2016
Clinical News

DRM01: Phase IIb data

Top-line data from a double-blind, U.S. and Canada Phase IIb trial in 420 patients with moderate to severe facial acne vulgaris showed that twice-daily 7.5% topical DRM01 met the co-primary endpoints of reducing mean inflammatory...
Items per page:
1 - 10 of 818